Prediction of Mild Cognitive Impairment that Evolves into Alzheimer's Disease Dementia within Two Years using a Gene Expression Signature in Blood: A Pilot Study
(2013) In Journal of Alzheimer's Disease 35(3). p.611-621- Abstract
- Background: The focus on Alzheimer's disease (AD) is shifting from dementia to the prodromal stage of the disorder, to a large extent due to increasing efforts in trying to develop disease modifying treatment for the disorder. For development of disease-modifying drugs, a reliable and accurate test for identification of mild cognitive impairment (MCI) due to AD is essential. Objective: In the present study, MCI progressing to AD will be predicted using blood-based gene expression. Material and Methods: Gene expression analysis using qPCR was performed on blood RNA from a cohort of patients with amnestic MCI (aMCI; n = 66). Within the aMCI cohort, patients progressing to AD within 1 to 2 years were grouped as MCI converters (n = 34) and the... (More)
- Background: The focus on Alzheimer's disease (AD) is shifting from dementia to the prodromal stage of the disorder, to a large extent due to increasing efforts in trying to develop disease modifying treatment for the disorder. For development of disease-modifying drugs, a reliable and accurate test for identification of mild cognitive impairment (MCI) due to AD is essential. Objective: In the present study, MCI progressing to AD will be predicted using blood-based gene expression. Material and Methods: Gene expression analysis using qPCR was performed on blood RNA from a cohort of patients with amnestic MCI (aMCI; n = 66). Within the aMCI cohort, patients progressing to AD within 1 to 2 years were grouped as MCI converters (n = 34) and the patients remaining at the MCI stage after 2 years were grouped as stable MCI (n = 32). AD and control populations were also included in the study. Results: Multivariate statistical method partial least square regression was used to develop predictive models which later were tested using leave-one-out cross validation. Gene expression signatures that identified aMCI subjects that progressed to AD within 2 years with a prediction accuracy of 74%-77% were identified for the complete dataset and subsets thereof. Conclusion: The present pilot study demonstrates for the first time that MCI that evolves into AD dementia within 2 years may be predicted by analyzing gene expression in blood. Further studies will be needed to validate this gene signature as a potential test for AD in the predementia stage. (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/3821341
- author
- organization
- publishing date
- 2013
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- Alzheimer's disease, biomarkers, diagnostic tests, gene expression, signatures, mild cognitive impairment
- in
- Journal of Alzheimer's Disease
- volume
- 35
- issue
- 3
- pages
- 611 - 621
- publisher
- IOS Press
- external identifiers
-
- wos:000318627800017
- scopus:84880195171
- pmid:23478308
- ISSN
- 1387-2877
- DOI
- 10.3233/JAD-122404
- language
- English
- LU publication?
- yes
- additional info
- The information about affiliations in this record was updated in December 2015. The record was previously connected to the following departments: Department of Psychogeriatrics (013304000)
- id
- 987d792b-545b-4030-af2e-fce2f57ec898 (old id 3821341)
- date added to LUP
- 2016-04-01 10:40:05
- date last changed
- 2022-05-06 00:15:00
@article{987d792b-545b-4030-af2e-fce2f57ec898,
abstract = {{Background: The focus on Alzheimer's disease (AD) is shifting from dementia to the prodromal stage of the disorder, to a large extent due to increasing efforts in trying to develop disease modifying treatment for the disorder. For development of disease-modifying drugs, a reliable and accurate test for identification of mild cognitive impairment (MCI) due to AD is essential. Objective: In the present study, MCI progressing to AD will be predicted using blood-based gene expression. Material and Methods: Gene expression analysis using qPCR was performed on blood RNA from a cohort of patients with amnestic MCI (aMCI; n = 66). Within the aMCI cohort, patients progressing to AD within 1 to 2 years were grouped as MCI converters (n = 34) and the patients remaining at the MCI stage after 2 years were grouped as stable MCI (n = 32). AD and control populations were also included in the study. Results: Multivariate statistical method partial least square regression was used to develop predictive models which later were tested using leave-one-out cross validation. Gene expression signatures that identified aMCI subjects that progressed to AD within 2 years with a prediction accuracy of 74%-77% were identified for the complete dataset and subsets thereof. Conclusion: The present pilot study demonstrates for the first time that MCI that evolves into AD dementia within 2 years may be predicted by analyzing gene expression in blood. Further studies will be needed to validate this gene signature as a potential test for AD in the predementia stage.}},
author = {{Roed, Line and Grave, Gisle and Lindahl, Torbjorn and Rian, Edith and Horndalsveen, Peter O. and Lannfelt, Lars and Nilsson, Christer and Swenson, Frank and Lonneborg, Anders and Sharma, Praveen and Sjogren, Magnus}},
issn = {{1387-2877}},
keywords = {{Alzheimer's disease; biomarkers; diagnostic tests; gene expression; signatures; mild cognitive impairment}},
language = {{eng}},
number = {{3}},
pages = {{611--621}},
publisher = {{IOS Press}},
series = {{Journal of Alzheimer's Disease}},
title = {{Prediction of Mild Cognitive Impairment that Evolves into Alzheimer's Disease Dementia within Two Years using a Gene Expression Signature in Blood: A Pilot Study}},
url = {{https://lup.lub.lu.se/search/files/2038290/4091342.pdf}},
doi = {{10.3233/JAD-122404}},
volume = {{35}},
year = {{2013}},
}